The filed complaint alleges that defendants made false statements and/or concealed that: (i) BioNTech overstated demand for and/or the commercial prospects of Comirnaty, the COVID-19 vaccine developed by the Company in collaboration with Pfizer ; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.